MichaelMilesWessMD

Journal Articles

• Clofarabine (Clolar®): Past, Present, and Future.  
  Kantarjian H, Jeha S, Gandhi V, Wess M and Faderl S, Leukemia and Lymphoma
• Deuterioglucose: Alteration of Biodistribution by an Isotope Effect.  
  Gatley S, Wess M, Govoni P, Katz J, and Friedman A, Journal of Nuclear Medicine
• Audiogenic Startle Reflex of Man and Its Relationship to Startle Syndrome.  
  Wilkins D, Hallet M, and Wess M, Brain
• Evoked Motor Response Duration: Differences in Aging between Males and Females.  
  Wess M and Fisher M, Muscle and Nerve
• Join now to see all

Abstracts/Posters

• The Pharmacodynamics of Zelapar®: Confirmation of MAO-B Selectivity.
  Wess M and Scott D, NeuroRx, American Society of Experimental Neurotherapeutics Meeting
• Pergolide (Permax®) Monotherapy Titration in Parkinson’s Disease.
  Nausieda P, Stern M, Hubble J, Silver D, Wess M, and Watts R, Movement Disorders, The 7th International Conference on Parkinson’s Disease and Movement Disorders
• Effects of TBC3711, A Novel EndothelinA Antagonist, on the Hemodynamics of Normal Healthy Males.
  Wess M, Mather J, and Davidson T, the 7th International Conference on Endothelin (ET-7) held, Edinburgh, Scotland
• Acute Stress Enhances Activity of the GABA Receptor Gated Chloride Ion Channel in Brain.
  Schwartz S, Wess M, Labrca R, Skolnick P, and Paul S, Brain Research
• Join now to see all

Lectures

• New Therapeutics in Parkinson’s Disease: Zelapar®. 
  The International Conference on Parkinson’s Disease, Beijing, China